(Tromsø, 21 June 2021) Reference is made to the Annual General Meeting
resolution on 20th May 2021, regarding share capital increase of 1,836,717 new
shares by contribution in kind.

The share capital increase pertaining to the issuance of the new shares under
the contribution in kind has now been registered with the Norwegian Register of
Business Enterprises. ArcticZymes Technologies' new registered share capital is
NOK 50,171,390 divided on 50,171,390 shares with a nominal value of NOK 1.00 per
share.
For more information, please contact :
Børge Sørvoll
CFO
+47 95290187
borge.sorvoll@arcticzymes.com
This information is subject to the disclosure requirements pursuant to Section 5
-12 the Norwegian Securities Trading Act.

This announcement was published by Børge Sørvoll, CFO of ArcticZymes
Technologies ASA, on 21 June 2021 at 15:05 (CEST).


About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre. ArcticZymes Technologies' IP and capabilities are
protected via a large portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.